P2.07-004 Immune-Related Adverse Events (irAEs) of Nivolumab Predicts Clinical Benefit in Advanced Lung Cancer Patients

Authors :: S. Yamanda
Shunichi Sugawara
K. Terayama
H. Ono
Y. Honda
T. Aiba
Ryoko Saito
Y. Kawashima
Atsushi Nakamura
K. Tsurumi
J. Sugisaka
K. Suzuki
Yuichiro Kimura
Y. Toi
S. Kawana
Y. Domeki
H. Shimizu
Source :: Journal of Thoracic Oncology. 12:S2417
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: 0301 basic medicine
Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
business.industry
medicine.disease
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Immune system
030220 oncology & carcinogenesis
Internal medicine
medicine
Medical emergency
Nivolumab
Lung cancer
Adverse effect
business

Full Text Access

Tools